JPH0555486B2 - - Google Patents
Info
- Publication number
- JPH0555486B2 JPH0555486B2 JP56144094A JP14409481A JPH0555486B2 JP H0555486 B2 JPH0555486 B2 JP H0555486B2 JP 56144094 A JP56144094 A JP 56144094A JP 14409481 A JP14409481 A JP 14409481A JP H0555486 B2 JPH0555486 B2 JP H0555486B2
- Authority
- JP
- Japan
- Prior art keywords
- glandular
- group
- coli
- strains
- hairs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000000762 glandular Effects 0.000 claims description 111
- 210000004209 hair Anatomy 0.000 claims description 82
- 229960005486 vaccine Drugs 0.000 claims description 33
- 241000588724 Escherichia coli Species 0.000 claims description 29
- 208000015181 infectious disease Diseases 0.000 claims description 17
- 210000004027 cell Anatomy 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 9
- 241001302580 Escherichia coli ETEC H10407 Species 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 210000000677 aggregate cell Anatomy 0.000 claims 1
- 241000894006 Bacteria Species 0.000 description 22
- 229920001817 Agar Polymers 0.000 description 13
- 239000008272 agar Substances 0.000 description 13
- 206010012735 Diarrhoea Diseases 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 238000002255 vaccination Methods 0.000 description 8
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000009260 cross reactivity Effects 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 6
- 230000008025 crystallization Effects 0.000 description 6
- 230000000741 diarrhetic effect Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 239000002054 inoculum Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010024769 Local reaction Diseases 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000035931 haemagglutination Effects 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 235000011130 ammonium sulphate Nutrition 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 235000010633 broth Nutrition 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 210000003495 flagella Anatomy 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 206010008631 Cholera Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 206010060708 Induration Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 210000003022 colostrum Anatomy 0.000 description 2
- 235000021277 colostrum Nutrition 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 235000021186 dishes Nutrition 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 208000031729 Bacteremia Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 206010063057 Cystitis noninfective Diseases 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000032754 Infant Death Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 102000041191 Type 1 family Human genes 0.000 description 1
- 108091061180 Type 1 family Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 201000005661 acute cystitis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- GZCGUPFRVQAUEE-KVTDHHQDSA-N aldehydo-D-mannose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O GZCGUPFRVQAUEE-KVTDHHQDSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 244000000007 bacterial human pathogen Species 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000003139 chronic cystitis Diseases 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 238000001446 dark-field microscopy Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 231100000174 enterotoxicity Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000011537 solubilization buffer Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 231100000901 systemic toxic effect Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/187,051 US4454116A (en) | 1977-11-23 | 1980-09-15 | Immunization of humans against enterotoxogenic infection by Escherichia coli |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5781417A JPS5781417A (en) | 1982-05-21 |
| JPH0555486B2 true JPH0555486B2 (fr) | 1993-08-17 |
Family
ID=22687411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56144094A Granted JPS5781417A (en) | 1980-09-15 | 1981-09-14 | Human immunity effect imparting vaccine against escherichia coli infectious desease |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5781417A (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ205392A (en) * | 1982-09-02 | 1987-03-06 | Unilever Plc | Preparation of immunoglobulins against e.coli pili |
-
1981
- 1981-09-14 JP JP56144094A patent/JPS5781417A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5781417A (en) | 1982-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4454116A (en) | Immunization of humans against enterotoxogenic infection by Escherichia coli | |
| Punsalang Jr et al. | Role of pili in the virulence of Neisseria gonorrhoeae | |
| Gilman et al. | Evaluation of a UDP-glucose-4-epimeraseless mutant of Salmonella typhi as a live oral vaccine | |
| Sack et al. | Progressive changes of Vibrio serotypes in germ-free mice infected with Vibrio cholerae | |
| JP3601602B2 (ja) | 無毒性微生物及びその使用：サルモネラ | |
| US4971794A (en) | Production of antibodies using a mixture of strains of E. coli collectively expressing type I pili, CFA I pili, CFA II pili and K88 pili | |
| CA1219806A (fr) | Production d'anticorps | |
| TW403655B (en) | Novel attenuated pseudomonas aeruginosa strains | |
| EP0048881B1 (fr) | Immunisation d'êtres humains contre une infection entérotoxogénique due à escherichia coli | |
| Gerber et al. | Attempts to transmit infectious mononucleosis to rhesus monkeys and marmosets and to isolate herpes-like virus | |
| EP0100710B1 (fr) | Vaccin pour l'immunisation des animaux et de l'homme contre le Toxoplasma Gondii | |
| Clarke et al. | Galactose epimeraseless mutants of Salmonella typhimurium as live vaccines for calves. | |
| KR910004868B1 (ko) | 인체 단일 클론항체 및 그것을 활성성분으로 함유하는 감염증의 예방 및 치료용 약학적 제제 | |
| US4454117A (en) | Immunization against infection by Escherichia coli | |
| EP0249739B1 (fr) | Composition d'un vaccin pour l'immunisation contre les infections provoquées à l'appareil urinaire par E. Coli | |
| JPH0555486B2 (fr) | ||
| WO1989012460A1 (fr) | Vaccines prepares a partir du pilus de l'haemophilus influenzae | |
| Miller et al. | Studies on the action of penicillin: VI. Further observations on the development of penicillin resistance by Meningococcus in vitro | |
| JPH08188515A (ja) | 組織培養物において効能のあるトキソプラズマ ゴンデイ ブラデイゾイトワクチンの生産 | |
| EP0114684A2 (fr) | Facteur toxoplasmique et sa production | |
| Jansson et al. | Search for mycoplasma in rheumatoid arthritis. | |
| WO1983000017A1 (fr) | Antigene pour anaplasma | |
| Felsenfeld et al. | Oral immunization with polyvalent streptomycin-dependent Escherichia coli vaccine | |
| Friedman | Absence of agglutinin formation in spleen cell cultures from immunologically tolerant mice | |
| Cann et al. | Epidemic Dysentery in the Nursing Staff due to Bacillus dysenteriae (Sonne) |